Conference Track

Hematologic Malignancies

Source: CCO Independent Conference Coverage of the 2008 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

New TKI Bosutinib Active in Chronic-Phase CML Resistant to Other TKIs
Novel JAK Inhibitor INCB018424 Active in Patients With Primary Myelofibrosis and Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Complete Remission Not Required for Azacitidine Survival Benefit in Patients With Higher-Risk MDS
Addition of Imatinib to Hyper-CVAD May Improve Outcomes in Patients With Ph-Positive Acute Lymphoblastic Leukemia
Frontline Subcutaneous Low-Dose Alemtuzumab Safe and Effective in Elderly CLL Patients With 17p Deletion
Interim Phase II Data Show Epratuzumab Added to R-CHOP Safe and Highly Effective as Initial DLBCL Therapy
Lenalidomide Plus Low-Dose Dexamethasone Safe and Highly Active With or Without SCT in Newly Diagnosed MM
Bortezomib/Dexamethasone Induction Prior to ASCT in Multiple Myeloma Patients Results in Superior Response Rates vs VAD Induction
Histone Deacetylase Inhibitor MGCD0103 Active in Relapsed/Refractory Hodgkin’s Lymphoma
Dose-Dense R-CHOP-14 Beneficial in Elderly Patients With Poor-Prognosis DLBCL
Lenalidomide Demonstrates Activity in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma
Temsirolimus Associated With PFS Improvement vs Other Treatments in Relapsed/Refractory Mantle Cell Lymphoma
High Response Rate With Induction PAD Followed by ASCT and Lenalidomide/Prednisone Consolidation in Older Patients With Multiple Myeloma
Addition of Bortezomib to Lenalidomide, Dexamethasone Active in Relapsed/Refractory Multiple Myeloma Patients With Manageable Toxicity Profile

Expert Analysis

Hematology

Program Director: Ramaswamy Govindan, MD

Faculty:

Andre Goy, MD, MPH
Hagop M. Kantarjian, MD
Sagar Lonial, MD

Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the roles of bortezomib and lenalidomide in first-line treatment of multiple myeloma
Describe the data on the use of tyrosine kinase inhibitors in leukemia and myelofibrosis
Summarize the approaches taken to improve on standard rituximab-CHOP in diffuse large B-cell lymphomas
Explain the rationale for mTOR and histone deacetylase inhibition in aggressive lymphomas
Relate the latest data on azacitidine in myelodysplastic syndromes

CME CREDIT INFORMATION

Release Date: 07/24/08

Expiration Date: 07/23/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.